Super Bug

Canadian fast-food companies failing when it comes to chicken welfare says new global report

Retrieved on: 
Tuesday, July 27, 2021
Restaurant chains, Restaurants, Fast-food restaurants, Pharmaceuticals policy, Veterinary medicine, Evolutionary biology, Antimicrobial resistance, Domino's Pizza, Starbucks, Subway, Chicken as food, Super Bug

Intensive farming methods also often rely on routine antibiotic use as a quick fix solution to keep stressed and sick animals alive.

Key Points: 
  • Intensive farming methods also often rely on routine antibiotic use as a quick fix solution to keep stressed and sick animals alive.
  • This over-use of antibiotics is fueling the deadly superbug crisis that kills over 700,000 people globally a year.
  • The latestreport called" Thepeckingorder 2021" ranksthesefast food restaurantsgloballyon how they are performing on their commitment, ambition, and transparency on chicken welfare in their supply chains.
  • Three companies received zero points for their Canadian policies - Starbucks, Subway and Domino's, although they have signed up to the BCC in other markets.

T2 Biosystems’ T2Resistance™ Panel is First Diagnostic to Graduate from CARB-X Portfolio

Retrieved on: 
Tuesday, September 24, 2019
Healthcare reform in the United States, Federal assistance in the United States, Presidency of Lyndon B. Johnson, Articles, Health, Economy, Antimicrobial resistance, Evolutionary biology, Medicare, Medicaid, Super Bug, T2S

Addressing the global superbug crisis requires urgent development of innovative diagnostics, like T2s technology, as well as new drugs and vaccines.

Key Points: 
  • Addressing the global superbug crisis requires urgent development of innovative diagnostics, like T2s technology, as well as new drugs and vaccines.
  • Being the first diagnostic to graduate from CARB-Xs portfolio is a significant milestone in the development of technology that has such capabilities.
  • T2 Biosystems is the company behind the T2Bacteria Panel, which was the first in-vitro diagnostic test to receive approval for a New Technology Add-on Payment (NTAP) by the United States Centers for Medicare & Medicaid Services (CMS).
  • The CARB-X portfolio is the worlds largest early development portfolio addressing drug-resistant bacteria, with 31 active projects.